SLC5A2 and diabetes mellitus: These agents selectively inhibit SGLT2 activity and promote urinary glucose excretion to reduce blood glucose without targeting the main pathology of type 2 diabetes mellitus (T2DM), such as insulin resistance and insulin hyposecretion [1].